Trial Profile
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2015
Price :
$35
*
At a glance
- Drugs Carlumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Centocor; Janssen Biotech
- 22 Oct 2015 Results published in the European Respiratory Journal
- 22 Oct 2015 Primary endpoint has not been met. (Rate of Percent Change (Relative to Baseline per 4 Week Interval) in Forced Vital Capacity (FVC) Through Week 52), as per article published in the European Respiratory Journal
- 22 Oct 2015 Dosing of this trial has been halted, based on the Interim analysis conducted after 24 weeks of dosing, as per an article published in the European Respiratory Journal